|
1
|
Corbacioglu S, Carreras E, Ansari M,
Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T,
Gruhn B, et al: Diagnosis and severity criteria for sinusoidal
obstruction syndrome/veno-occlusive disease in pediatric patients:
A new classification from the European society for blood and marrow
transplantation. Bone Marrow Transplant. 53:138–145. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ortega JA, Donaldson SS, Ivy SP, Pappo A
and Maurer HM: Venoocclusive disease of the liver after
chemotherapy with vincristine, actinomycin D, and cyclophosphamide
for the treatment of rhabdomyosarcoma. A report of the intergroup
rhabdomyosarcoma study group. Childrens cancer group, the pediatric
oncoloy group, and the pediatric intergroup statistical center.
Cancer. 79:2435–2439. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sulis ML, Bessmertny O, Granowetter L,
Weiner M and Kelly KM: Veno-occlusive disease in pediatric patients
receiving actinomycin D and vincristine only for the treatment of
rhabdomyosarcoma. J Pediatr Hematol Oncol. 26:843–846.
2004.PubMed/NCBI
|
|
4
|
Arndt C, Hawkins D, Anderson JR, Breitfeld
P, Womer R and Meyer W: Age is a risk factor for
chemotherapy-induced hepatopathy with vincristine, dactinomycin,
and cyclophosphamide. J Clin Oncol. 22:1894–1901. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saito H, Maruyama I, Shimazaki S, Yamamoto
Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M
and Aoki N: Efficacy and safety of recombinant human soluble
thrombomodulin (ART-123) in disseminated intravascular coagulation:
Results of a phase III, randomized, double-blind clinical trial. J
Thromb Haemost. 5:31–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abeyama K, Stern DM, Ito Y, Kawahara K,
Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et
al: The N-terminal domain of thrombomodulin sequesters
high-mobility group-B1 protein, a novel anti-inflammatory
mechanism. J Clin Invest. 115:1267–1274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Loghmani H and Conway EM: Exploring
traditional and nontraditional roles for thrombomodulin. Blood.
132:148–158. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walterhouse DO, Pappo AS, Meza JL,
Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR,
Meyer WH and Hawkins DS: Shorter-duration therapy using
vincristine, dactinomycin, and lower-dose cyclophosphamide with or
without radiotherapy for patients with newly diagnosed low-risk
rhabdomyosarcoma: A report from the soft tissue sarcoma committee
of the children's oncology group. J Clin Oncol. 32:3547–3552. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wada H, Takahashi H, Uchiyama T, Eguchi Y,
Okamoto K, Kawasugi K, Madoiwa S and Asakura H; Diagnostic and
therapeutic guidelines for hemophagocytic lymphohistiocytosis, :
The approval of revised diagnostic criteria for DIC from the
Japanese Society on thrombosis and hemostasis. Thromb J. 15:172017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Henter JI, Horne A, Aricó M, Egeler RM,
Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski
J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allen CE, Yu X, Kozinetz CA and McClain
KL: Highly elevated ferritin levels and the diagnosis of
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
50:1227–1235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DeLeve LD, Shulman HM and McDonald GB:
Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome
(veno-occlusive disease). Semin Liver Dis. 22:27–42. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeLeve LD, Ito Y, Bethea NW, McCuskey MK,
Wang X and McCuskey RS: Embolization by sinusoidal lining cells
obstructs the microcirculation in rat sinusoidal obstruction
syndrome. Am J Physiol Gastrointest Liver Physiol. 284:G1045–G1052.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szabo G and Petrasek J: Inflammasome
activation and function in liver disease. Nat Rev Gastroenterol
Hepatol. 12:387–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmidt-Arras D and Rose-John S: IL-6
pathway in the liver: From physiopathology to therapy. J Hepatol.
64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sato K, Hall C, Glaser S, Francis H, Meng
F and Alpini G: Pathogenesis of kupffer cells in cholestatic liver
injury. Am J Pathol. 186:2238–2247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanwar VS, Albuquerque ML, Ribeiro RC,
Kauffman WM and Furman WL: Veno-occlusive disease of the liver
after chemotherapy for rhabdomyosarcoma: Case report with a review
of the literature. Med Pediatr Oncol. 24:334–340. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adachi N and Matsuda I: Veno-occlusive
disease of the liver after combined adjuvant chemotherapy for a
1-year-old boy with rhabdomyosarcoma: Potential usefulness of the
gabexate mesylate (FOY). J Pediatr Gastroenterol Nutr. 14:314–318.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D'Antiga L, Baker A, Pritchard J, Pryor D
and Mieli-Vergani G: Veno-occlusive disease with multi-organ
involvement following actinomycin-D. Eur J Cancer. 37:1141–1148.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cecen E, Uysal KM, Ozguven A, Gunes D,
Irken G and Olgun N: Veno-occlusive disease in a child with
rhabdomyosarcoma after conventional chemotherapy: Report of a case
and review of the literature. Pediatr Hematol Oncol. 24:615–621.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen IL, Yang SN, Hsiao CC, Wu KS and
Sheen JM: Treatment with high-dose methylprednisolone for hepatic
veno-occlusive disease in a child with rhabdomyosarcoma. Pediatr
Neonatol. 49:141–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi A, Kang YK, Lim S, Kim DH, Lim JS and
Lee JA: Severe hepatic sinusoidal obstruction syndrome in a child
receiving vincristine, actinomycin-D, and cyclophosphamide for
rhabdomyosarcoma: Successful treatment with defibrotide. Cancer Res
Treat. 48:1443–1447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kernan NA, Richardson PG, Smith AR,
Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R,
Tappe W, et al: Defibrotide for the treatment of hepatic
veno-occlusive disease/sinusoidal obstruction syndrome following
nontransplant-associated chemotherapy: Final results from a post
hoc analysis of data from an expanded-access program. Pediatr Blood
Cancer. 65:e272692018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scaffidi P, Misteli T and Bianchi ME:
Release of chromatin protein HMGB1 by necrotic cells triggers
inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ulfgren AK, Grundtman C, Borg K,
Alexanderson H, Andersson U, Harris HE and Lundberg IE:
Down-regulation of the aberrant expression of the inflammation
mediator high mobility group box chromosomal protein 1 in muscle
tissue of patients with polymyositis and dermatomyositis treated
with corticosteroids. Arthritis Rheum. 50:1586–1594. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurokohchi K, Imataki O and Kubo F:
Anti-inflammatory effect of recombinant thrombomodulin for
fulminant hepatic failure. World J Gastroenterol. 21:8203–8207.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei F, Liu S, Luo L, Gu N, Zeng Y, Chen X,
Xu S and Zhang D: Anti-inflammatory mechanism of ulinastatin:
Inhibiting the hyperpermeability of vascular endothelial cells
induced by TNF-α via the RhoA/ROCK signal pathway. Int
Immunopharmacol. 46:220–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
